1. 316 Phase I study of lurbinectedin (PM01183) in combination with cisplatin (C) with or without aprepitant (Ap) in patients (pts) with advanced solid tumors. (September 2015) Authors: Forster, M.; Sessa, C.; Von Moos, R.; Brown, N.; Metaxas, Y.; Griguolo, G.; Lardelli, P.; Coronado, C.; Juan, L.; Fernandez-Teruel, C.; Soto-Matos, A.; Stathis, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 335 Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors. (September 2015) Authors: Garralda, E.; Stathis, A.; Drilon, A.; Boni, V.; Hyman, D.; Calvo, E.; Griguolo, G.; Makker, V.; Doger, B.; Canziani, L.; Varghese, A.M.; Jimenez, E.; Luque, J.; Soto-Matos, A.; Szyldergemajn, S.; Sessa, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 340 A phase I study of the smoothened (SMO) antagonist LDE225 in combination with paclitaxel in patients with advanced solid tumors. (September 2015) Authors: Stathis, A.; Hess, D.; Xyrafas, A.; Enoiu, M.; Berardi, S.; Moos, R. Von; Homicsko, K.; Griguolo, G.; Jörger, M.; Mark, M.; Ackermann, C.; Sessa, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors. (December 2016) Authors: Massard, C.; Soria, J.C.; Stathis, A.; Delord, J.P.; Awada, A.; Peters, S.; Lewin, J.; Bekradda, M.; Rezai, K.; Zeng, Z.; Azher, H.; Perez, S.; Siu, L. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A systematic review of contemporary phase I trials in patients with lymphoma. (December 2022) Authors: Griguolo, G.; Zorzi, M.F.; Pirosa, M.C.; Treglia, G.; Bertoni, F.; Kuruvilla, J.; Zucca, E.; Stathis, A. Journal: Critical reviews in oncology/hematology Issue: Volume 180(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors. (December 2021) Authors: Martorana, F.; Colombo, I.; Treglia, G.; Gillessen, S.; Stathis, A. Journal: Cancer treatment reviews Issue: Volume 101(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. CD30 and lymphomas: the clue for four?. (2019) Authors: Mangas, C.; Polino, A.; Stathis, A.; Leoni-Parvex, S.; Marazza, G.; Zucca, E.; Mainetti, C. Journal: European journal of cancer Issue: Volume 119(2019)Supplement 1 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. (8th March 2016) Authors: Gaudio, E.; Tarantelli, C.; Kwee, I.; Barassi, C.; Bernasconi, E.; Rinaldi, A.; Ponzoni, M.; Cascione, L.; Targa, A.; Stathis, A.; Goodstal, S.; Zucca, E.; Bertoni, F. Journal: Annals of oncology Issue: Volume 27:Number 6(2016:Jun.) Page Start: 1123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. COMBINATORIAL SCREENING OF THE PI3K INHIBITOR COPANLISIB IN T CELL LYMPHOMAS. (June 2017) Authors: Gaudio, E.; Kwee, I.; Spriano, F.; Tarantelli, C.; Rinaldi, A.; Jourdan, T.; Berthold, M.; Arribas, A.; Stathis, A.; Rossi, D.; Liu, N.; Lange, M.; Politz, O.; Zucca, E.; Bertoni, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS. (12th June 2019) Authors: Tarantelli, C.; Lange, M.; Gaudio, E.; Cascione, L.; Spriano, F.; Kwee, I.; Arribas, A.; Rinaldi, A.; Jourdan, T.; Berthold, M.; Margheriti, F.; Gritti, G.; Rossi, D.; Stathis, A.; Liu, N.; Zucca, E.; Politz, O.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗